Divisiong of Nephrology and Hypertension




Douglas J. Norman, MD

Douglas J. Norman, M.D.
Professor of Medicine
Director, Transplant Medicine
Director, Laboratory of Immunogenetics and Transplantation

Back to faculty page



Douglas J. Norman, M.D.

Dr. Norman directs the Medical Transplantation Program in the Department of Medicine, and is the Medical Director of the Laboratory of Immunogenetics and Transplantation. He is a past president of both the American Society of Transplantation and the United Network for Organ Sharing (UNOS). His major clinical interests are renal transplant medicine and Immunogenetics. His primary research interests are clinical Immunogenetics and immunosuppression for clinical transplantation. He is currently a member of the clinical trials oversight group for the Immune Tolerance Network.


B.A. - Stanford University, 1968
M.D. - University of Washington, 1972


Intern - San Francisco General Hospital, 1972-1973
Internal Medicine - University of California Hospitals, San Francisco 1973-1974
Senior Resident in Medicine, Beth Israel Hospital, Boston 1975-1976


Nephrology - Peter Bent Brigham Hospital, Boston, MA 1976-1977
Affiliating Nephrology Fellow, Children's Hospital Medical Center, Boston, MA 1977
Research Fellow in Transplantation Immunology and Immunogenetics, Peter Bent Brigham Hospital, Boston, MA 1977-1979

Research Interest:
  • Clinical Immunogenetics, immunosuppression for clinical transplantation.
Clinical Interest:

Renal transplant medicine and Immunogenetics.

Representative Publications:
  • Ellison MD, Norman DJ, Breen TJ, Edwards EB, Davies DB, Daily OP. No effect of H-Y minor histocompatibility antigen in zero-mismatched living-donor renal transplants. Transplantation. 1994;58(4):518-520.
  • Norman DJ. Allograft rejection: prevention and treatment: antilymphocyte antibodies. In: Massry, Glassock, eds. Textbook of Nephrology. Baltimore, Md: Williams and Wilkins; 1994(87):1655-1660.
  • Henell KR, Norman DJ. In vivo pharmacodynamics of Atgam induction immunosuppression in renal transplantation. Transplantation Proceedings. 1995;27(1):1052-1053.
  • Norman DJ. Allocation of livers for liver transplantation: ethics and politics. In: Keeffe E., ed. Clinics in Liver Disease: Liver Transplantation. Philadelphia, Pa: W.B. Saunders Co.; 1997:281-286.
  • Norman DJ. Expected clinical outcomes of kidney transplantation and risk factors. In: Norman DJ and Suki WN, eds. ASTP Primer on Transplantation. Thorofare, Nj: Slack Inc.; 1997:245-250.
  • Norman DJ. Renal transplantation: immunosuppression and postoperative management. In: Greenberg A, ed. Primer on Kidney Diseases. 2nd ed. San Diego, Ca: National Kidney Foundation; 1998:482-488.
  • de Mattos AM, Bennett WM, Barry JM, Norman DJ. HLA-identical sibling renal transplantation - a 21 year single center experience. Clin Transplant. 1999 April;13(2):158-67.
  • Alkhunaizi AM, de Mattos AM, Barry JM, Bennett WM, Norman DJ. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation. 1999 May;67(10):1319-24.
  • Lewis MS, Wilson RA, Walker K, Stegeman-Olsen J, Norman DJ, Barry JM, Bennett WM. Factors in cardiac risk stratification of candidates for renal transplant. J Cardiovasc Risk. 1999 Aug;6(4):251-5.
  • Gallay BJ, de Mattos AM, Norman DJ. Reversible acute renal allograft dysfunction due to gabapentin. Transplantation. 2000 July 15;70(1):208-9